Please provide your email address to receive an email when new articles are posted on . Specialized psychological intervention was not found more efficacious than control conditions in improving ...

A large meta-analysis sheds light on the best antipsychotic maintenance strategy to prevent relapse in clinically-stable schizophrenia — with some unexpected results that have potential implications ...

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...

Please provide your email address to receive an email when new articles are posted on . Clozapine and second-generation long-acting formulations of certain antipsychotics decreased risk for ...

Panelists discuss how relapse intensifies clinical and economic burdens, reinforcing the need for adherence and prevention-focused care. Panelists discuss how relapse is one of the most significant ...

The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically ...

Switching to clozapine after a first schizophrenia relapse was associated with a lower risk of second relapse compared with other strategies, a population-based cohort study in Finland found. The risk ...